Board of Directors
Dr. Craig Hopkinson, has more than 25 years of experience building and leading clinical development organizations and medical affairs groups. He has led multidisciplinary development teams in a range of therapeutic areas, including neuroscience, oncology, gastroenterology, infectious diseases, cardiovascular conditions, inflammation, genetic diseases, hematology and neurodegenerative diseases. Dr. Hopkinson currently serves as Executive Vice President of Research & Development and Chief Medical Officer at Alkermes. In this role, Dr. Hopkinson leads the company’s Discovery, Pharmaceutical Development, Early Stage Clinical Development, Late Stage Clinical Development, Regulatory Affairs, Clinical Operations, PMO and Medical Affairs functions. He is responsible for the strategic development and execution of clinical development programs for the company’s pipeline of drug candidates.
Before joining Alkermes in 2017, Dr. Hopkinson served as Senior Vice President of Medicines Development and Head of Global Medical Affairs at Vertex Pharmaceuticals. Prior to this role, Dr. Hopkinson held various leadership positions at Eisai Pharmaceuticals, Elan Pharmaceuticals, Actelion Pharmaceuticals and Pfizer.
Dr. Hopkinson earned a Bachelor of Medicine and Bachelor of Surgery at the University of the Orange Free State in South Africa.
-
David Chiswell, Ph.D. – ChairmanFormer CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP
-
Susan AlesinaVice President, National Business Development and Alliances, Boston Children’s Hospital
-
Ron CooperPresident and Chief Executive Officer
-
Habib DableFormer President and CEO, Acceleron Pharma; Currently Independent Director, Blueprint Medicines Corporation, and Venture Partner, RA Capital Management, L.P.
-
Michael Gutch, Ph.D.Chief Financial Officer, Noema Pharma
-
Stephanie S. Okey, M.S.Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company
-
Davey S. ScoonFormer CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors